trial

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCTId NCT02188121
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 227 (actual)
Sponsored by Mclean Hospital
Primary completion 2020-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
227 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-02
Primary completion
2020-10
Eligibility
ALL · 18 Years · 89 Years

Interventions & indications

Drugs
SimvastatinLosartan

Sponsors

Mclean HospitalLead Sponsor
Michael J. Gill Mental Health ClinicCollaborator
Massachusetts Mental Health CenterCollaborator
Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General HospitalCollaborator
The Edinburg CenterCollaborator

Investigators

1
Dost Ongur, MD, PhDPrincipal Investigator

Sites

1 total
Belmont, United States

Facts & assertions

4 sourced
Enrollment
227
Phase
PHASE4
Primary Completion Date
2020-10
Status
COMPLETED
relationships
The graph out of here
drug
Simvastatin
drug
Losartan
drug
lead_sponsor
Mclean Hospital
company
collaborator
Michael J. Gill Mental Health Clinic
company
Massachusetts Mental Health Center
company
indication
Bipolar Disorder
indication
Major Depressive Disorder
indication
Cardiovascular Disease
indication
investigator
Dost Ongur, MD, PhD
person